Telix Pharmaceuticals Limited
Narrative signal
Telix Pharmaceuticals Limited’s revenue growth stands at 55.8% for Dec 2024. Year-over-year, the metric shifted by −158.1 pts, translating into a −73.89% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
Valuation Signals
Track how the market prices earnings, book value, and operating cash flow for rapid context on relative multiples.
Price-to-Earnings Ratio
163.3x
Price-to-Sales Ratio
10.4x
Price-to-Book Ratio
14.3x
EV / EBITDA
86.7x
Dividend Yield
0%
Profitability Pulse
Follow margin structure and return ratios that benchmark execution quality and capital efficiency.
Growth Momentum
Gauge the trajectory of revenue, earnings, and free cash flow expansion to understand durability.
Cash & Balance Sheet
Monitor liquidity, leverage, and free cash flow capacity that underpin resilience across cycles.
AlphaPilot quick take
• Telix Pharmaceuticals Limited trades at $9.85 with a market footprint around $3.3B.
• Operating within Healthcare — Biotechnology offers instant peer context.
• Dashboard highlight: revenue growth at 55.8%, refreshed from the live fundamentals feed.
• Pivot into AlphaPilot deep dives to benchmark valuation, execution, and resilience.
Company profile
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Telix Pharmaceuticals Limited (TLX) stock FAQs
Quick answers sourced from live Financial Modeling Prep fundamentals and AlphaPilot portfolio guidance.
What is Telix Pharmaceuticals Limited (TLX) stock price today?
Telix Pharmaceuticals Limited (TLX) trades near $9.85 as of Dec 5, 2025, 9:00 PM. Quotes refresh throughout the trading day in USD via Financial Modeling Prep, which powers the AlphaPilot dashboard.
What is Telix Pharmaceuticals Limited's market capitalization?
Telix Pharmaceuticals Limited's equity is valued around $3.3B, based on the latest share price multiplied by shares outstanding reported to Financial Modeling Prep.
What is the 52-week range for Telix Pharmaceuticals Limited?
Telix Pharmaceuticals Limited's 52-week range runs from $8.76 — $30.36. Comparing the current price to this band helps visualize positioning versus the past year's highs and lows.
How active is trading in Telix Pharmaceuticals Limited stock?
Telix Pharmaceuticals Limited most recently moved about 61.3K shares. Elevated volume often signals strong investor interest or fresh catalysts.
Does Telix Pharmaceuticals Limited pay a dividend?
Telix Pharmaceuticals Limited currently yields roughly 0%. Dividend yield divides the last 12 months of payouts by the latest share price, providing a quick income snapshot.
What is Telix Pharmaceuticals Limited's intraday trading range?
Telix Pharmaceuticals Limited has traded between $9.80 — $9.93 so far today. Monitoring the intraday span highlights short-term volatility relative to the longer 52-week range.
Where does the Telix Pharmaceuticals Limited stock data come from?
AlphaPilot sources quotes, fundamentals, and intraday chart data for Telix Pharmaceuticals Limited from the Financial Modeling Prep institutional API. The summary page blends live pricing with fundamentals that refresh after every earnings release or regulatory filing.